CorMedix (CRMD) News Today

CorMedix Inc. (NASDAQ: CRMD) has been supported by improved longer-term earnings expectations and a higher analyst price target, although the outlook remains mixed because near-term quarterly losses are expected to continue. The stock has recently traded above both its 50-day and 200-day moving averages, suggesting improving momentum, but it remains well below its 12-month high.

• Positive Sentiment: HC Wainwright raised its FY2027 EPS forecast to $0.14 from $0.01 and its FY2028 forecast to $0.54 from $0.39. The upgrades imply stronger expected profitability as CorMedix’s commercial business scales. CorMedix FY2026 EPS Forecast Boosted by HC Wainwright
• Positive Sentiment: CorMedix’s price target was reportedly increased to $14.00, representing substantial upside from recent trading levels and signaling analyst confidence in the company’s longer-term prospects. CorMedix Price Target Raised to $14.00
• Positive Sentiment: HC Wainwright also improved its Q3 2026 EPS forecast to a loss of $0.05 per share from a loss of $0.08, indicating expectations for somewhat better near-term results.
• Neutral Sentiment: An investment analysis described CorMedix as having a durable commercial base but identified 2027 as an important test for sustained growth, profitability and execution. CorMedix: Durable Commercial Base, But 2027 Is The Real Test
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS forecast to a loss of $0.08 from a loss of $0.06. The revision indicates that profitability may be uneven before the projected improvement in 2027 and 2028.

Overall, the news is modestly positive for CRMD: longer-term earnings revisions and the higher price target outweigh the small deterioration in the Q4 2026 forecast, while investors will likely focus on whether CorMedix can convert its commercial base into consistent profits.